Glossopharyngeal neuralgia
diseaseOn this page
Also known as glossopharyngeal nerve neuralgiaGlossovasopharyngeal neuralgianeuralgia of glossopharyngeal nerve
Summary
Glossopharyngeal neuralgia (MONDO:0016372) is a disease and 5 clinical trials. Top therapeutic interventions include galcanezumab. A subtype of glossopharyngeal nerve disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 28
- Clinical trials: 5
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.7 | United States | Validated |
Signs & symptoms
Clinical features (HPO)
28 HPO clinical features (Orphanet curated; top 28 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000716 | Depression | Frequent (30-79%) |
| HP:0000739 | Anxiety | Frequent (30-79%) |
| HP:0001293 | Cranial nerve compression | Frequent (30-79%) |
| HP:0030164 | Jaw claudication | Frequent (30-79%) |
| HP:0030766 | Ear pain | Frequent (30-79%) |
| HP:0030811 | Tongue pain | Frequent (30-79%) |
| HP:0032148 | Episodic pain | Frequent (30-79%) |
| HP:0200025 | Mandibular pain | Frequent (30-79%) |
| HP:3000047 | Abnormal glossopharyngeal nerve morphology | Frequent (30-79%) |
| HP:0000174 | Abnormal palate morphology | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001279 | Syncope | Occasional (5-29%) |
| HP:0001605 | Vocal cord paralysis | Occasional (5-29%) |
| HP:0001609 | Hoarse voice | Occasional (5-29%) |
| HP:0001662 | Bradycardia | Occasional (5-29%) |
| HP:0001824 | Weight loss | Occasional (5-29%) |
| HP:0002315 | Headache | Occasional (5-29%) |
| HP:0002617 | Dilatation | Occasional (5-29%) |
| HP:0002664 | Neoplasm | Occasional (5-29%) |
| HP:0002960 | Autoimmunity | Occasional (5-29%) |
| HP:0003319 | Abnormality of the cervical spine | Occasional (5-29%) |
| HP:0004395 | Malnutrition | Occasional (5-29%) |
| HP:0007099 | Chiari type I malformation | Occasional (5-29%) |
| HP:0011968 | Feeding difficulties | Occasional (5-29%) |
| HP:0012534 | Dysesthesia | Occasional (5-29%) |
| HP:0032043 | Odynophagia | Occasional (5-29%) |
| HP:0100008 | Schwannoma | Occasional (5-29%) |
| HP:0200136 | Oral-pharyngeal dysphagia | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | glossopharyngeal neuralgia |
| Mondo ID | MONDO:0016372 |
| Orphanet | 221098 |
| DOID | DOID:14423 |
| SNOMED CT | 43763009 |
| UMLS | C0154731 |
| MedGen | 57595 |
| GARD | 0006519 |
| MedDRA | 10018391 |
| Anatomy (UBERON) | UBERON:0001649 |
| Is cancer (heuristic) | no |
Also known as: glossopharyngeal nerve neuralgia · glossopharyngeal neuralgia · Glossovasopharyngeal neuralgia · neuralgia of glossopharyngeal nerve
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy › glossopharyngeal nerve disorder › glossopharyngeal neuralgia
Related subtypes (4): vagus nerve disorder, glossopharyngeal nerve neoplasm, glossopharyngeal nerve paralysis, glossopharyngeal motor neuropathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04158752 | PHASE4 | COMPLETED | Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia |
| NCT02321566 | PHASE1 | TERMINATED | Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain. |
| NCT06931457 | Not specified | RECRUITING | Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet Rich Plasma to Treat Idiopathic Glossopharyngeal Neuralgia (GPN) |
| NCT07135024 | Not specified | NOT_YET_RECRUITING | Prospective Register Study to Assess Eligibility for and Efficacy of Surgical Treatment in Patients With nEuRovascular Conflict |
| NCT05257655 | Not specified | COMPLETED | Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| GALCANEZUMAB | 4 | 1 |
Related Atlas pages
- Drugs: Galcanezumab